Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088465 · ClinicalTrials.gov registry record · Phase 3
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 931
- Enrollment target
NCT00088465 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 931 participants.
The verdict
NCT00088465, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 931 participants
- Enrollment target
Study Summary
This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot. Key objectives of the study are to: * Determine how well intramuscular (IM) olanzapine depot works during long-term treatment, * Evaluate the safety and tolerability of IM olanzapine depot during long-term treatment, * Determine the blood levels of IM olanzapine depot in patients during long-term treatment
Interventions
- DRUG Intramuscular olanzapine depot
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 931 participants |
| Start Date | 2004-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088465
The ClinicalTrials.gov registry entry for NCT00088465 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 931 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intramuscular olanzapine depot is the first listed.
NCT00088465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088465 about?
NCT00088465 is a clinical study titled "Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder". This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot. Key objectives of the study are to: * Determine how well intramuscular (IM) olanzapine depot works during long-term treatment, ...
What is the current status of trial NCT00088465?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 931 participants. The study started on 2004-08. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00088465?
The interventions under investigation include: Intramuscular olanzapine depot (DRUG).
Who is sponsoring clinical trial NCT00088465?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.